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Ultrasound elastographyAbstract Objective: Treatment for hepatitis C infection and monitoring of progression were
based on degree of ﬁbrosis, which were traditionally diagnosed by liver biopsy but it has many lim-
itations. We aim to evaluate noninvasive imaging methods, so-called diffusion-weighted MRI (DW
MRI) and transient elastography [(TE), ﬁbroscan] in diagnosing liver ﬁbrosis in hepatitis C (HCV)
patients.
Patients: The Study included 102 hepatitis C patients (62 male) with mean age of 38 ± 5. For all
patients liver biopsy was done followed by DWMRI and TE. METAVIR classiﬁcation system was
used for staging liver ﬁbrosis. Data obtained were collected and results of DW MRI and TE were
compared with those of histopathology. The diagnostic performance of ADC and TE was deter-
mined using areas under receiver operating characteristic (AUROC) curves for signiﬁcant ﬁbrosis
PF3.
Results: Measuring ADC at different b-values had a signiﬁcant negative correlation with stage of
ﬁbrosis P= 0.001, the best negative correlation at b-value of 700 mm2/s. TE had a signiﬁcant posi-
tive correlation with stage of ﬁbrosis P= 0.005. Both examination showed a signiﬁcant difference
between ﬁbrosis stage <F3 and stages PF3 with P< 0.00 for ADC measure at each b-value and
TE respectively.
280 F. Zaiton et al.Conclusion: This study suggests that DWMRI and TE had favorable comparable results with liver
biopsy for the diagnosis of signiﬁcant liver ﬁbrosis.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Patients with hepatitis B and hepatitis C virus infections are at
high risk for development of hepatic ﬁbrosis that proceeds to
cirrhosis, once cirrhosis occurs the risk of complication as
portal hypertension and hepatocellular carcinoma increases
(1), liver ﬁbrosis in chronic liver disease results from excessive
accumulation of an extracellular matrix in response to chronic
inﬂammation. Viral hepatitis C infection represents the most
common cause of hepatic ﬁbrosis in Egypt (2).
The assessment of liver ﬁbrosis in patients with viral
hepatitis is essential not only to determine prognosis but also
to select patients who are in need for antiviral therapy (3,4).
Liver biopsy was the standard reference method for evaluation
of liver ﬁbrosis (3), but it has several limitations such as
hemorrhage, pain, interobserver variability, sampling errors
and also it lacks the patient acceptance (5).
This made the need for a noninvasive, fast, safe and reliable
method that allows evaluation of liver ﬁbrosis, and repetitive
measurements for monitoring disease progression and treat-
ment response (5).
These non invasive methods include routine biochemical
and hematological liver function tests, serum markers of
connective tissue, and scoring systems using a combination
of clinical and/or laboratory tests. Unfortunately, these meth-
ods had a failure rate reaching about 50% of the patients to
quantify liver ﬁbrosis (6).
Recently, a wide variety of non invasive promising imaging-
based methods had been used for assessing hepatic ﬁbrosis,
including ultrasound, CT and MRI (7). The measurement of
liver stiffness with ultrasound transient elastography (ﬁbro-
scan) was proven to be accurate in the detection of signiﬁcant
ﬁbrosis in patients with hepatitis C. However, transient elas-
tography (TE) cannot be used in obese patients or patients
with ascites or narrow intercostal spaces (6,8,9).
Magnetic resonance imaging (MRI) based techniques, such
as diffusion weighted magnetic resonance imaging (DW-MRI)
and measuring apparent diffusion coefﬁcient (ADC) value
have become an important noninvasive diagnostic tool in the
evaluation of liver ﬁbrosis. DW MRI allows whole liver exam-
ination with an insight into distribution of liver ﬁbrosis permit-
ting detection of the most affected liver segments (5).
The aim of this study is to evaluate the diagnostic perfor-
mance of non invasive technique used in measuring the liver
stiffness as measuring ADC value in diffusion weighted mag-
netic resonance imaging DW MRI and ﬁbroscan (FS) in diag-
nosis of liver ﬁbrosis in patients with hepatitis C virus (HCV)
infection.
2. Patients and methods
2.1. Study population
This prospective study was conducted at Radiology and Inter-
nal Medicine Departments, Zagazig University Hospitals,Egypt, between June 2011 and May 2013, and included all
patients having hepatitis C of any severity, aged P18 years
old and referred to our department for ultrasound guided liver
biopsy.
Chronic hepatitis C was proven by using standard diagnos-
tic techniques (detection of hepatitis C antibodies and positive
serum HCV-RNA by polymerase chain reaction for six
months). Exclusion criteria were: (1) patients with other
chronic liver diseases as hepatitis B, metabolic disease, fatty
liver or focal mass in the liver either benign or malignant;
(2) patients classiﬁed as ﬁbrosis stage 0 (F0) according to
METAVIR scoring system (10); (3) contraindications to
biopsy (e.g. pregnancy, ascites); (4) patients with body mass
index (BMI) > 28 kg/m2; (5) contraindication to MRI exami-
nation; (6) previous liver transplant; (7) known malignancy or
other terminal disease and (8) patients refused to undergo
biopsy or to participate in the study.
The study protocol was approved by the local ethics
committee. And an informed consent was obtained from all
patients before participating in the study.
From 132 referred patients, only 102 met the inclusion
criteria and completed the study, there were 62 males and 40
females. Their age ranged from 19 to 52 years with mean age
of 38 ± 5.
All patients subjected to full clinical and laboratory evalu-
ation, liver biopsy followed by transient elastography and
MRI evaluation.
Liver ﬁbrosis stages were evaluated according to the
METAVIR scoring system (16). Fibrosis (F) was staged on a
ﬁve-point scale as follows: F0 = no ﬁbrosis; F1 = portal
ﬁbrosis without septa; F2 = portal ﬁbrosis and few septa;
F3 = numerous septa without cirrhosis; F4 = cirrhosis (16).
2.2. Clinical and laboratory evaluation
Clinical parameters were determined for all patients including
age, weight, height, duration of the disease, past history of
ascites or bleeding varices. Laboratory evaluation included li-
ver function test, platelet count, and prothrombin time.
2.3. Liver biopsy
Percutaneous liver biopsy was done before MRI and TE with
mean time of delay 10 ± 6 days; (range, 9–30 days). Liver
biopsy was taken by an experienced radiologist with ultrasound
guidance using a 16–18 gauge needle. Liver biopsy samples were
ﬁxed in formalin, embedded in parafﬁn, and stained with hema-
toxylin–eosin and Masson trichrome. The mean size of liver
biopsy specimens was 18 mm (range: 15–21 mm). All samples
were analyzed by a pathologist, blinded to clinical results.
2.4. Radiological evaluation
All patients were subjected to both TE and MRI, either of the
technique was done ﬁrst according to the availability or both
done at same sitting, with an interval time ranging from the
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Both TE and MRI evaluated by different radiologists, who
were unaware of the results of the other exam.2.4.1. Transient elastography
Transient elastography was performed using FibroScan
(Philips – iU22 xMATRIX). The idea of TE in measuring liver
stiffness is based on eliciting elastic shear wave propagating
through the liver tissue, followed by pulse-echo ultrasound
acquisitions. Their velocity is measured and is directly related
to the degree of liver stiffness. The examination was done by
applying the probe over the right lobe of the liver through
the intercostal spaces, while patients lay supine with the right
arm abducted over the head and breathing normally (11).
TE measure liver stiffness in a volume of nearly a cylinder
1 cm wide and 4 cm long at 25 and 65 mm below the skin
surface, the area must be devoid of any large vascular
structures.2.4.1.1. Interpretation of results. Ten successful measurements
were performed, and the median value of these measurements
was considered as a value for liver stiffness, expressed in
kilopascal (kPa). The machine software determines if the
measurement is successful or not (unsuccessful measuring gives
no reading). Liver stiffness values range from 2.5 to 75 kPa.
The result is immediately available, and it is operator-independent.
Only examinations with 10 valid measurements and a success rate
of at least 60% were considered reliable.Table 1 Demographic data of the patient and ﬁbrosis stages
by liver biopsy.
Patient characteristics Value
M/F patients (%) * 62(60.8%)/40(39.2%)
Patient age (y) 38 ± 5
Duration of the disease (year) 2 ± 7
Body mass index (kg/m2) 24 ± 8.3
AST level (UI/I) 51 ± 23
ALT level (UI/I) 73 ± 45
GGT level (UI/I) 120 ± 65
Total bilirubin level (mg/dL) 10.5 ± 18
Platelet count (103/mm3) 198 ± 76
Fibrosis stages (liver biopsy results)2.4.2. b-DW MRI examination
DWI of the liver was performed on a 1.5 Tesla MR scanner
(Philips Medical Systems, Achieva). A transverse single-shot
echo-planar imaging sequence was performed using a quadra-
ture phased-array coil with respiratory and ﬁnger pulse
triggering.
We used multiple diffusion sensitivities of b-values (200,
500, 700 and 1000 s/mm2), with the following acquisition
parameters: average TR of 1300–1600 ms; ET of 60–86 ms;
matrix size of 256 · 256; ﬁeld of view of 32–40 cm; bandwidth
of 1736 Hz/pixel; number of excitation = 2; slice thick-
ness = 6 mm; gap = 1 mm number of slices = 30, average
(respiratory cycle dependent) acquisition time = 2 min.
DW MRI was performed without intravenous contrast
injection.
ADC maps were formed automatically by MRI software
regions of interest (ROIs) approximately 1–1.5 cm in diameter
was placed in four locations within the liver for each b value
and the combination of all b values. ADCs were measured in
the lateral and medial segments of the left lobe and the anterior
and posterior segments of the right lobe, considering avoiding
the site of GB and liver vasculature. The ﬁnal ADC was the
average of the four ROIs. A routine MRI examination of
the liver was performed after the DWI sequence only if clini-
cally indicated.F1 35(34.3%)*
F2 22(21.6%)*
F3 25(24.5%)*
F4 20(19.6%)*
* Data are given as mean ± SD or n (%).2.5. Data interpretation
Data for each patient were collected, and the results of TE and
MRI were compared with those of the histopathology.2.6. Statistical analyses
All data were reported as mean, slandered deviation and pro-
portions. Patients ADC value of liver stiffness at different b
values was compared using the repeated measures of ANOVA
test, and for values of TE we used one-way analysis of variance
(F or ANOVA) test and the values followed the least signiﬁ-
cant difference (LSD). The impact of speciﬁc predictors of dis-
cordance on ADC and TE performance was determined using
areas under receiver operating characteristic (AUROC) curves
for signiﬁcant ﬁbrosis PF3. AUROCs were compared using
the method of DeLong et al. (12). All analyses were performed
using (Spss 16). P-values < 0.05 and 0.001 were considered
statistically signiﬁcant and highly signiﬁcant respectively.
3. Results
This study included 102 patients with hepatitis C virus, they
were 62 males and 40 females. Their age ranged from 19 to
52 years with mean age of 38 ± 5. The mean duration of the
disease was 2 ± 7/years, the BMI (kg/m2) ranged from 17.8
to 28 with mean BMI of 22 ± 8.3, all patients undergone liver
biopsy and staged according to METAVIR scoring system;
including 35 patients in F1; 22 patients in F2; 25 patients in
F3 and 20 patients in F4. The demographic data of the patients
and the results of liver biopsy are illustrated in Table 1.
3.1. Mean ADC values and ﬁbrosis stages
The mean ADC values for each stages of liver ﬁbrosis using
different b values (200, 500, 700, 1000) was shown in Table 2.
There is evident negative correlation between the ADC value
and degree of ﬁbrosis at each b-values, the r value was 0.935,
0.927, 0.965 and 0.898 with b value of 200, 500, 700 and
1000 respectively, l P value 0.001 which is highly signiﬁcant,
the best negative correlation was achieved at a b value of 700.
Comparing mean hepatic ADC between patients with
ﬁbrosis stages <F3 versus ﬁbrosis stage PF3 (Table 3), there
was a highly signiﬁcant difference at the mean hepatic ADC at
each b-values between the two groups (P-value = 0.000).
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The value of liver stiffness by FS ranged from 4.2 to 72.5 kPa
with a mean value of 5.7 ± 0.81.
The values of liver stiffness measurement by transient elas-
tography increased with an increase the stage of ﬁbrosis from
F1 to F4 with a signiﬁcant positive correlation (r = 0.879;
P < 0.001), it is lower for patients with stages F1 and F2 than
stages F3 and F4. Table 4 shows the mean values of LSM
stratiﬁed by stage of ﬁbrosis (see Figs. 1–4).
3.3. Mean hepatic ADC values and transient elastography
performance in liver ﬁbrosis
Receiver operating characteristics (ROC) curve analysis was
used to evaluate the ability of hepatic ADC (at different b-val-
ues 200, 500, 700 and 1000 mm2/s) and transient elastography
to predict liver ﬁbrosis stages <F3 versus PF3, the best cut
off value of mean hepatic ADC was 2.17 · 103,
1.66 · 103 mm2/s, 1.62 · 103 mm2/s and 1.59 · 103 mm2/s
at b-value of 200,500,700 and 1000 respectively, while the cut
off value of transient elastography was 12.95 kPa (above this
value patient belongs to ﬁbrosis stage <F3 and below this
value the patient belongs to stage PF3), the sensitivity,
speciﬁcity, positive predictive value (PPV) and negative
predictive value (NPV) as well as degree of signiﬁcance for
mean ADC at each b-value and TE is shown in Table 5.
4. Discussion
Liver ﬁbrosis (LF) in chronic hepatitis C progresses as the
period of infection prolongs, and may reach liver cirrhosis with
the increase in the risk of development of hepatocellular carci-
noma (13), the accurate assessment of LF is very important in
order to predict the prognosis and start the appropriate
prophylactic therapy to prevent disease progression (11).
In patients with chronic viral hepatitis, the liver biopsies are
used to assess prognosis, guide antiviral therapy, and predict
treatment efﬁcacy (1,14), liver biopsy still the gold standard
method for evaluation of liver ﬁbrosis in hepatitis C patients,
but there are many drawbacks for liver biopsy as: it is invasive
methods, the liver specimen obtained from a single area out of
the whole liver mass (these lead to high sample inaccuracy
owing to the patchy distribution of liver ﬁbrosis) (15), sample
size may affect the results obtained, liver biopsy is contraindi-
cated in patients with ascites or abnormal coagulation proﬁle
which is frequently encountered in patients with advanced
ﬁbrosis or cirrhosis due to chronic hepatitis C, moreover there
are 10–20% of inter- and intraobserver disagreement in rating
the degree of ﬁbrosis was reported (15–17). From other pointTable 2 The mean ADC values of different stages of liver ﬁbrosis
Fibrosis stage N b-Values (mm2/s)
b= 200 b= 500
F1 35 2.26 ± 0.3 1.85 ± 0
F2 22 1.88 ± 0.11 1.64 ± 0
F3 25 1.75 ± 0.06 1.61 ± 0
F4 20 1.44 ± 0.01 1.37 ± 0of view liver biopsy has poor patient acceptance and the risk
of complication is still present such as, bleeding, pain, infec-
tions, anxiety, pneumo or hemothorax, injury to biliary tree
leading to hemobilia or bile peritonitis, puncture of adjacent
organ as the kidney and the intestine, and even death with a
mortality rate of 1:1,000–1:10,000 (1,16,18–20)
These limitations increased the need for a fast, safe and reli-
able technique to assess liver ﬁbrosis and to follow up progres-
sion or regression of the disease during treatment (7). Recently
developed non invasive methods, such as the sonographic
based technique as transient elastography (FibroScan, Echo-
sens) (8,21,22), and MRI based techniques as measuring
ADC value in diffusion weighted-MRI, perfusion-weighted
MRI and MR elastography represent major advances in the
prediction of ﬁbrosis and cirrhosis (1,21,23).
The use of DW MRI in the assessment of liver ﬁbrosis is
based on altered diffusion of water protons in ﬁbrotic tissue
(24). Many previous studies had advised the use of multiple
b-values to obtain accurate quantitative analysis of DW
images and consequently reliable ADC map as well as the
ADC measurement. They proposed that at low b-values the
ADC measurement was not reliable for accurately assessed
diffusion of the tissue due to the mixed effect of perfusion
and diffusion that could not be separated at this level
(1,5,25–27).
In our study, we used multiple b values of 200, 500, 700,
1000 mm2/s, also to eliminate the effect of perfusion, we
did not use small b-value in order to obtain accurate ADC
measurement in accordance with Kovac et al. (5), and HR
Ibrahim et al. (25). While in a study of Taouli et al. (1), Zhu
et al. (26)and Girometti et al. (27), they used b value of
0 mm2/s.
Previous studies reported that ADC values were signiﬁ-
cantly lower values in cirrhotic liver compared with normal
liver (9,28–32), these may be due to the presence of a larger
amount of connective tissue deposited within the liver,
narrowed sinusoids, and altered blood ﬂow (33).
In our study, we found a negative correlation between ADC
values and stages of liver ﬁbrosis according to METAVIR
scoring system which is signiﬁcant at all b values (r= 0.935,
0.927, 0.965, 0.898 for b-value of 200, 500, 700 and
1000 mm2/s respectively). The best negative correlation was
achieved by b-value of 700 and the least negative correlation
seen at b-value = 1000.
This negative correlation was matched with many pub-
lished studies (1,5,25–27,34), but unlike our study the best
negative correlation was achieved at b-value of 500 in study
of zhu et al (26) this difference may be owed to the use of
different b-values.
Owing to current treatment strategy, the diagnosis of stage
2 or greater ﬁbrosis is clinically important because, due to cost,(value · 103 mm2/s).
P value
b= 700 b= 1000
.03 1.71 ± 0.01 1.53 ± 0.01 0.001
.04 1.52 ± 0.05 1.36 ± 0.03 0.001
.05 1.45 ± 0.05 1.30 ± 0.04 0.001
.03 1.29 ± 0.01 1.04 ± 0.01 0.001
Table 3 Comparison of mean hepatic ADC at each value between stages <F3 and stages PF3.
b-values (mm2/s) Mean ADC P value
Stage <F3 (n= 57) Stage PF3 (N= 45)
b= 200 2.21 ± 0.09 1.71 ± 0.23 0.000
b= 500 2.21 ± 0.09 1.71 ± 0.23 0.000
b= 700 1.71 ± 0.02 1.45 ± 0.10 0.000
b= 1000 1.49 ± 0.0 1.26 ± 0 0.000
Table 4 The mean LSM stratiﬁed by stage of ﬁbrosis.
Fibrosis stage N Mean Liver stiﬀness, kPa (range) P value
F1 35 6.06 ± 0.71 0.001
F2 22 10.88 ± 3.79 0.001
F3 25 14.58 ± 4.86 0.001
F4 20 35.96 ± 10.83 0.001
KPa value was expressed as mean ± SD.
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or greater ﬁbrosis should receive antiviral treatment (14).
ADC measures in our study can perform well in
differentiating the patients into two groups <F3 and PF3
ﬁbrosis, there is a signiﬁcant difference in mean hepaticFig. 1 31 year-old male patient with chronic hepatitis C virus (ﬁbr
single-shot echo-planar diffusion-weighted images obtained at different
mm2 (d). The calculated mean ADC value was 2.29 · 103 mm2/
respectively for each b-value.ADC measurement at all examined b-values between patients
at different stages of liver ﬁbrosis (P values was 0.001). Fur-
thermore, there was highly signiﬁcant difference in mean hepa-
tic ADC when comparing patients with ﬁbrosis stage <F3 and
those with stage PF3 (P value = 0.000), these were in agree-
ment with (1,5,25).
ROC analysis of prior DW MRI studies, reported AUC
values of 0.783–0.790 for the detection of liver ﬁbrosis stage
P2 and 0.717–0.92 for the detection of ﬁbrosis stage P3
(5,15,22,35), in consistent with these studies our results showed
AUC values ranging from 0.937 to 0.898 for differentiating
stages < and PF3.
ADC cut off values of advanced ﬁbrosis, and cirrhosis
varied in previous literature, a value of 1.41 · 103 mm2/s de-
scribed by (1), 0.88 · 103 mm2/s by (14), 1.11 · 103 mm2/s
by (27), and more recently 1.63 · 103 mm2/s by (5), theseosis stage 1 on liver biopsy). ADC mapping of breath-hold axial
b-values, b= 200 s/mm2 (a), 500 s/mm2 (b), 700 s/mm2 (c), 1000 s/
s, 1.85 · 103 mm2/s, 1.73 · 103 mm2/s, and 1.53 · 103 mm2/s
Fig. 2 Fibroscan (transient elastography) ultrasound of same
patient in Fig. 1, liver stiffness measurement equal to 6.61 kPa.
Fig. 4 Fibroscan (transient elastography) ultrasound of same
patient in Fig. 3, liver stiffness measurement equal to 15.31 kPa.
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ADC measuring. We found a cut off value of 2.17 · 103,
1.66 · 103 mm2/s, 1.62 · 103 mm2/s and 1.59 · 103 mm2/s
at b-value of 200, 500, 700 and 1000 mm2/s respectively in
the current study for differentiating stages < and PF3.
By using ROC curve we obtain, a sensitivity of 86.7%,
80%, 93.3% and 86.7%, and with speciﬁcity of 66.7%,Fig. 3 49 year-old male patient with chronic hepatitis C virus (ﬁbr
single-shot echo-planar diffusion-weighted images obtained at different
mm2 (d). The calculated mean ADC value was 1.75 · 103 mm2/
respectively for each b-value.93.3%, 93.3% and 46.7% for b-values 200, 500, 700 and
1000 mm2/s respectively, but the best predictive value was
achieved with b-value 700 mm2/s with high sensitivity of
93.3%, speciﬁcity of 93.3%, the PPV of 93.3% and NPV of
93.3%, and the least predictive value was at b-value of
1000 mm2/s, these may be attributed to the risk of noise
contamination at high b-value.osis stage 3 on liver biopsy). ADC mapping of breath-hold axial
b-values, b= 200 s/mm2 (a), 500 s/mm2 (b), 700 s/mm2 (c), 1000 s/
s, 1.63 · 103 mm2/s, 1.45 · 103 mm2/s, and 1.29 · 103 mm2/s
Table 5 Receiver Operating Characteristics Curve (ROC) for ADC (200–1000) and FS for quantiﬁcation of liver ﬁbrosis stage F< 3
versus ﬁbrosis stage PF3.
AUC (95% CI) Cut oﬀ value Sensitivity Speciﬁcity PPV NPV Kappa value P
ADC 200 mm2/s 0.937 (0.835–1.023) 2.17 · 103 mm2/s 86.7% 66.7% 72.2% 83.3% 0.533 0.000
ADC 500 mm2/s 0.971 (0.918–1.029) 1.66 · 103 mm2/s 80% 93.3% 92.3% 82.4% 0.733 0.000
ADC 700 mm2/s 0.991 (0.981–1.010) 1.62 · 103 mm2/s 86.7% 83.7% 81.9% 77.8% 0.633 0.000
ADC 1000 mm2/s 0.898 (0.784–1.016) 1.59 · 103 mm2/s 93.3% 93.3% 93.3% 93.3% 0.867 0.000
TE 0.935 (0.89–0.98) 12.95 kPa 91.1% 78.9% 77.9% 91.8% 0.688 0.005
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promising utility for using DW-MRI and ADC measurement
in quantiﬁcation of liver ﬁbrosis with reported sensitivity,
and speciﬁcity ranged from 84% to 92.3% and 76% to
92.1%, respectively (1,5,36).
But in a study of Sandrasegaran et al. (34), they described a
signiﬁcant difference of ADC values of F0 (non ﬁbrosis) and
F4 (cirrhosis) P= 0.008 but we differ in our study as there
were better differentiation between individual stages of liver
ﬁbrosis. Also Zhu et al. (26), described a best predictive value
at 500 mm2/s with sensitivity of 84% and speciﬁcity of 80%
and the least value at 200 mm2/s, these may be owed to the
difference at the used b-value.
There was also difference between our study and Taouli
et al. (1), as they evoked that ADC cannot perform well in
differentiating individual stages of ﬁbrosis, this could be due
to limited number of patients and intermediate stages of ﬁbro-
sis in Taouli et al. (1) study. However we agree with Taouli
et al. (1) who reported that ADC was a signiﬁcant predictor
of stage PF3 versus 6F2, but they had best correlation at
b-value of 1000 with sensitivity of 80% and speciﬁcity of 90%.
A higher speciﬁcity of 100% had been reported by
Girometti et al. (27)., but in their study they included healthy
individuals and cirrhotic patients only.
TE has become an important tool for the noninvasive
assessment of ﬁbrosis (7,37). Some recent extensive studies,
have demonstrated that measurement of liver stiffness with
ﬁbroscan is a good alternative for liver biopsy (38).
Our results show that liver stiffness measurement with
transient elastography had a signiﬁcant positive correlation
with ﬁbrosis stage from F1 to F4 with P-value of 0.005, with
mean kPa value ranged from 6.06 ± 0.71, 10.88 ± 3.79,
14.58 ± 4.86, 35.96 ± 10.83 at stage F1, F2, F3 and F4
respectively with P value of 0.005.
Many previous studies reported that transient elastography
correlated positively with the histological score of liver ﬁbrosis
D (5,8,16,22,39,40).
We also detected a signiﬁcant difference in liver stiffness
measurement using TE between patients with liver ﬁbrosis of
stages f3 with P value 0.000, these were in agreement with.
(5,39).
In previous published studies, the cut off value reported for
diagnosis of ﬁbrosis of stages >F3 ranged from 9.5 to 9.6 kPa
(8,11,22,38,40,41) In the present study, we recorded a similar
cut off value of 9.8 kPa. However, foucher et al. (16) described
a higher cut off value of 12.5 kPa, and they attributed this dif-
ference due to the study population that included patients with
chronic liver disease of various etiologies.
Using ROC analysis, we recorded the cutoff point of TE at
8.9 to be a signiﬁcant predictor for differentiation betweenﬁbrosis stage <F3 and those >F3 with AUC 0.935 (conﬁ-
dence interval (CI) 95%: 0.88–0.98), and sensitivity 91.1%,
speciﬁcity 78.9%, PPV 77.4%, NPV 91.8%, and P-value of
0.000.
In other published studies in accordance with our result,
AUROC (95% conﬁdence interval) was 0.80 (0.75–0.84) for
patients with signiﬁcant ﬁbrosis (F> 2), 0.90 (0.86–0.93) for
patients with severe ﬁbrosis (F3) and 0.96 (0.94–0.98) for
patients with cirrhosis (F4) (38,42–44).
Adebajo et al. (44) performed a systematic review and
diagnostic accuracy meta-analysis of studies comparing ultra-
sound-based TE to liver biopsy for the detection of hepatic
ﬁbrosis they found six fully published studies (42,45–49) were
identiﬁed for analysis, and they concluded that in the ﬁve
studies that evaluated signiﬁcant ﬁbrosis were identiﬁed.
Among these studies, the pooled estimates were 83% for
sensitivity [95% conﬁdence interval (CI) 77–88%], 83% for
speciﬁcity (95% CI 77–-88%), 4.95 for the positive likelihood
ratio (95% CI 3.4–7.2), 0.17 for the negative likelihood ratio
(95% CI 0.09–0.35), and 30.5 for the diagnostic odds’ ratio
(95% CI 12.8–72.4). The other ﬁve studies that assessed
cirrhosis; the pooled estimates were 98% for sensitivity (95%
CI 90–100%), 84% for speciﬁcity (95% CI 80–88%), 7 for
the positive likelihood ratio (95% CI 2.8–17.3), 0.06 for the
negative likelihood ratio (95% CI 0.02–0.19), and 130 for
the diagnostic odds’ ratio (95% CI 36.5–462.1). Our result
was nearly falling in the range described in these studies.
We recorded a PPV and NPV of 77.4% and 91.8% respec-
tively similar to that reported in many previous studies that
described positive and negative predictive values ranging from
70% to 95% and 77% to 95%, respectively (7,8,16,48).
Our results show that the diagnostic performance of the
non invasive technique we used (DW MRI and TE) was
reliable and accurate with good sensitivity, speciﬁcity, PPV
and NPV in assessing liver ﬁbrosis, and the result of both tests
was comparable to each other. Measuring degree of liver stiff-
ness by applying ADC value and TE can give signiﬁcant results
in assessing the stage of liver ﬁbrosis according to METAVIR
staging, also a signiﬁcant difference was obtained by both tech-
niques in differentiating patients with ﬁbrosis stage F3.
The advantage over biopsy is that both techniques are non
invasive, well accepted by the patients, painless, easy and safe
with no risk of complication.
Ultrasound has more advantage as it is of low cost, wide-
spread, rapid, can be done at bed side or outpatient clinics.
There are some technical limitations of TE, as obesity (partic-
ularly the fatness of the chest wall), narrow intercostal space
and ascites. Moreover, Fraquelli et al. (50) found that TE
reproducibility is signiﬁcantly reduced in patients with
steatosis.
286 F. Zaiton et al.While the advantage of DW MRI and ADC measurement
would be in its ability to give a diagnosis about liver ﬁbrosis
distribution, with ADC measurements in each liver segment.
Moreover, it could be done in obese patients and patients with
ascites without affection of accuracy of the results.
Furthermore, DW MRI has slight higher sensitivity and
speciﬁcity over TE. Limitations related to: the availability of
the high-performance scanner; the presence of experienced
personnel; the examination takes long time, especially if
conventional MRI is added. (7).
We had limitations in this study, ﬁrst we did not evaluate
the effect of iron overload, and edema on stiffness and mea-
surement by TE and ADC, second the use of multiple b-value
in ADC measurement gives a wide range of variability in
measurement.
On the other hand, the strength of our study was that we
include only hepatitis C patients, exclusion of patients with
high BMI >28 or steatosis to decrease the error of measure-
ment by TE, and lastly we did not use small b-value in ADC
measurement to eliminate the effect of perfusion.
In conclusion, TE and DW MRI were promising tech-
niques, and they can replace liver biopsy as they can accurately
diagnose staging liver ﬁbrosis, mainly the advanced stages, the
choice between both techniques depends on the clinician and
the general condition of the patients or the presence of contra-
indications for either techniques, furthermore, the advantage
of MRI in measuring ADC value in different liver segments
thus gives information about the exact distribution of liver
ﬁbrosis adding to its accuracy. More important advantage
about the use of non invasive techniques in measuring liver
stiffness is that it can be used for monitoring response to treat-
ment and evaluation of progression or regression of the
disease.
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